Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2024. For the period, the company expects revenue of ¥26,190 million, Operating profit of ¥3,470 million, Profit attributable to owners of parent of ¥3,975 million or ¥95.47 basic per share.
Shin Nippon Biomedical Laboratories, Ltd.
Equities
2395
JP3379950003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,502 JPY | +1.49% | +5.55% | -11.54% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.54% | 397M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- 2395 Stock
- News Shin Nippon Biomedical Laboratories, Ltd.
- Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024